Program At Intercept News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
CAMBRIDGE, Mass., March 9, 2021 /PRNewswire/  Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of Jason Campagna, M.D., Ph.D. as Chief Medical Officer. Dr. Campagna brings more than 15 years of biotech and pharmaceutical experience to the Q32 Bio executive team during a critical growth and development period for the company.  
We are delighted to welcome Jason to Q32 Bio as our Chief Medical Officer, said Mike Broxson, Chief Executive Officer of Q32 Bio. Jason provided critical guidance in the early days of the company, serving as a trusted clinical counselor as we ve advanced our groundbreaking tissue-targeted complement program ADX-097 towards the clinic. His extensive experience leading clinical development programs and strong background in academic research will complement our leadership team in our mission to restore immune homeostasis in patie ....

United States , United Kingdom , Jason Campagna , Mike Broxson , Medicines Company , Bio Inc , Program At Intercept , Intercept Pharmaceuticals , Atlas Venture , University Of Miami , Critical Care At Harvard Medical School , University Of Pennsylvania , Health Science Lead Of Surgery , Neuroplasticty Research Group , Cottage Health System , Chief Medical , Chief Medical Officer , Chief Executive Officer , Primary Biliary Cholangitis , Non Alcoholic Steatohepatitis , Senior Vice President , Health Science Lead , Chief Medical Quality Officer , Massachusetts General , Cellular Pharmacology , Critical Care ,